<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Estradiol and norethindrone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Estradiol and norethindrone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Estradiol and norethindrone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12434" href="/d/html/12434.html" rel="external">see "Estradiol and norethindrone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708751"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Endometrial cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular disease:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Do not use estrogen-alone therapy for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (0.625 mg) alone, relative to placebo.</p>
<p style="text-indent:-2em;margin-left:2em;">Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke, and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Breast cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The Women's Health Initiative (WHI) estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dementia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Do not use estrogen-alone therapy for the prevention of dementia. The WHI Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years and older during 5.2 years of treatment with daily conjugated estrogens (0.625 mg) alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p>
<p style="text-indent:-2em;margin-left:2em;">Do not use estrogen plus progestogen therapy for the prevention of dementia. The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years or older during 4 years of treatment with daily conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk vs benefit:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Only daily oral conjugated estrogen (CE) 0.625 mg was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F167186"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Activella;</li>
<li>Amabelz;</li>
<li>CombiPatch;</li>
<li>Lopreeza [DSC];</li>
<li>Mimvey</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912007"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Activelle;</li>
<li>Activelle LD;</li>
<li>Estalis</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F167201"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Estrogen and Progestin Combination</li></ul></div>
<div class="block doa drugH1Div" id="F167188"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6684f5e6-d09f-43ef-a1bd-5ea9171e77f2">Osteoporosis prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis prevention:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Activella, Amabelz, Lopreeza: Estradiol 1 mg/norethindrone 0.5 mg or estradiol 0.5 mg/norethindrone 0.1 mg: One tablet daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Mimvey: Estradiol 1 mg/norethindrone 0.5 mg: One tablet daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Mimvey Lo: Estradiol 0.5 mg/norethindrone 0.1 mg: One tablet daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33847005-a8a0-48f0-b6fe-f3530ab1256e">Secondary amenorrhea, hypoestrogenism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary amenorrhea, hypoestrogenism: </b>
<b>Note: </b>Combination products are only indicated for patients with a uterus; the progestogen (ie, a natural progesterone or synthetic progestin) component prevents estrogen therapy-associated endometrial hyperplasia. For functional hypothalamic amenorrhea (FHA), initiate only if menses have not returned after 6 to 12 months of nonpharmacologic (eg, behavioral, lifestyle) therapy. For hypoestrogenism due to other causes (eg, primary ovarian insufficiency), may initiate after diagnosis confirmed if no contraindications (eg, breast cancer) (ACOG 2017; ES [Gordon 2017]; Nelson 2009; Popat 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal</b> (CombiPatch): Estradiol 0.05 mg/norethindrone acetate 0.14 mg per day <b>or</b> estradiol 0.05 mg/norethindrone acetate 0.25 mg per day: Apply 1 patch twice weekly. Initiate with lower dose; may increase after 6 months if higher dose of progestin is needed (eg, for irregular menstrual bleeding).<b> Note:</b> For twice-weekly dosing, replace patch every 3 to 4 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy: </b>If amenorrhea is expected to be transient (eg, FHA), discontinue after ~18 months to assess for recovery (Ackerman 2019; Ackerman 2020; Gordon 2017). If amenorrhea is expected to be permanent (eg, primary ovarian insufficiency), continue at least until the average age of natural menopause (age ~50 years) (ACOG 2017; Kalantaridou 2000; Nelson 2009).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause:</b>
<b> Note<i>:</i></b>For use in symptomatic patients who are &lt;60 years of age or within 10 years of menopause who do not have contraindications to hormone therapy (eg, breast cancer) (NAMS 2022). Nonoral estrogen preparations are preferred in patients with hypertriglyceridemia, risk factors for venous thromboembolic disease, active gallbladder disease, and/or migraine headache with aura (Martin 2022; Renoux 2010). Combination products are only indicated for patients with a uterus; the progestogen (ie, a natural progesterone or synthetic progestin) component prevents estrogen therapy-associated endometrial hyperplasia. Use of a combination product offers less dosing flexibility for initiating and tapering estrogen compared to separate estrogen and progestogen products.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Estradiol 0.5 mg/norethindrone 0.1 mg <b>or</b> estradiol 1 mg/norethindrone 0.5 mg: 1 tablet daily. <b>Note:</b> Initiate at the lowest dose and increase after ~4 weeks as needed to relieve symptoms (Martin 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal </b>(CombiPatch, Estalis [Canadian product]):</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous combined regimen: Estradiol 0.05 mg/norethindrone acetate 0.14 mg per day <b>or</b> estradiol 0.05 mg/norethindrone acetate 0.25 mg per day: Apply 1 patch twice weekly. <b>Note:</b> For twice-weekly dosing, replace the patch every 3 to 4 days. Initiate with lower dose; may increase after 3 to 6 months if higher dose of progestin is needed (eg, for irregular menstrual bleeding).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> Not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer and with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (NAMS 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3679489c-0513-47c2-abaf-018b39b0ff61">Vulvar and vaginal atrophy associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vulvar and vaginal atrophy associated with menopause:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Activella, Activelle [Canadian product], Amabelz, Lopreeza, Mimvey: Estradiol 1 mg/norethindrone 0.5 mg: One tablet daily</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Estradiol 0.05 mg/norethindrone acetate 0.14 mg per day or estradiol 0.05 mg/norethindrone acetate 0.25 mg per day</p>
<p style="text-indent:-2em;margin-left:6em;">CombiPatch:</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous combined regimen: Apply 1 patch twice weekly</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous sequential regimen: Apply estradiol-only patch for first 14 days of cycle, followed by 1 CombiPatch applied twice weekly for the remaining 14 days of a 28-day cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Estalis [Canadian product]: Continuous combined regimen: Apply a new patch twice weekly during a 28-day cycle</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990128"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987440"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated with hepatic dysfunction or disease.</p></div>
<div class="block doe drugH1Div" id="F167189"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The Beers Criteria recommends avoiding systemic estrogen therapy in postmenopausal patients ≥65 years of age (independent of diagnosis or condition). In older postmenopausal patients already taking systemic estrogens, consider deprescribing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>). Duration of use is not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, non-oral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35797481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35797481'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F167164"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Peripheral edema (transdermal: 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Headache (11% to 25%), pain (transdermal: 15% to 19%), depression (transdermal: 8% to 9%), insomnia (6% to 8%), dizziness (transdermal: 6% to 7%), nervousness (transdermal: 3% to 6%), emotional lability (oral: 1% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash (transdermal: 5% to 6%), acne vulgaris (transdermal: 4% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Menstrual disease (transdermal: 6% to 19%), weight gain (oral: ≤9%), ovarian cyst (oral: 3% to 7%), breast hypertrophy (transdermal: 2% to 7%), hypermenorrhea (transdermal: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea (transdermal: 9% to 14%), abdominal pain (transdermal: 6% to 14%), nausea (3% to 12%), dyspepsia (transdermal: 6% to 8%), flatulence (transdermal: 5% to 7%), gastroenteritis (oral: 2% to 6%), constipation (transdermal: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Mastalgia (transdermal: 25% to 48%; oral: 17% to 24%), dysmenorrhea (transdermal: 20% to 31%), vaginal hemorrhage (oral: 26%; transdermal: 3% to 6%), vaginitis (transdermal: 6% to 13%), postmenopausal bleeding (oral: 5% to 11%), leukorrhea (transdermal: 5% to 10%), endometrial hyperplasia (oral: ≤1% to 10%), abnormal pap smear (transdermal: 8%), vulvovaginal candidiasis (oral: 4% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Uterine fibroids (oral: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Infection: Infection (transdermal: 3% to 5%), viral infection (oral: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Application site reaction (transdermal: 6% to 23%)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Back pain (6% to 15%), weakness (transdermal: 8% to 13%), arthralgia (transdermal: 6%), limb pain (oral: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Rhinitis (transdermal: 13% to 22%), nasopharyngitis (oral: 21%), upper respiratory tract infection (oral: 10% to 18%), sinusitis (7% to 15%), flu-like symptoms (transdermal: 9% to 14%), respiratory tract disease (transdermal: 9% to 13%), pharyngitis (transdermal: 4% to 10%), bronchitis (transdermal: 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Accidental injury (3% to 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Alopecia, altered blood pressure, anaphylactoid reaction, anaphylaxis, angioedema, bloating, breast tenderness, carbohydrate intolerance, cerebrovascular accident, cervical polyp, change in appetite, change in cervical secretions, change in corneal curvature, change in libido, chloasma, cholelithiasis, cholestatic jaundice, chorea, contact lens intolerance, cystitis-like syndrome, dementia, edema, endometrial carcinoma, erythema multiforme, erythema nodosum, exacerbation of asthma, exacerbation of endometriosis, exacerbation of porphyria, fallopian tube disease (cyst), fatigue, fibrocystic breast changes, galactorrhea, gallbladder disease, hemorrhagic eruption, hirsutism, hypersensitivity, hypertension, increased serum transaminases, increased serum triglycerides, irregular menses, irritability, leg cramps, loss of scalp hair, malignant neoplasm of breast, migraine, mood changes, myalgia, myocardial infarction, nipple discharge, ovarian carcinoma, pancreatitis, paresthesia, premenstrual-like syndrome, pruritus, pulmonary thromboembolism, retinal thrombosis, seborrhea, significant cardiovascular event, skin discoloration, stomach cramps, thrombophlebitis, uterine fibroids (size increased), uterine spasm, varicose veins, venous thromboembolism, vertigo, vomiting, weight loss</p></div>
<div class="block coi drugH1Div" id="F167175"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Angioedema, anaphylactic reaction, or hypersensitivity to estradiol or any component of the formulation; undiagnosed abnormal genital bleeding; deep vein thrombosis or pulmonary embolism (current or history of); active or history of arterial thromboembolic disease (eg, stroke, myocardial infarction); breast cancer (known, suspected, or history of); estrogen-dependent tumor (known or suspected); hepatic impairment or disease; known protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Known, suspected, or history of estrogen-dependent or progestin-dependent malignant neoplasm (eg, endometrial cancer); endometrial hyperplasia; porphyria; partial or complete loss of vision associated with ophthalmic vascular disease; active thrombophlebitis; classical migraine; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F167161"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Anaphylaxis requiring emergency medical management has been reported and may develop at any time during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: Based on data from the Women's Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in patients who are postmenopausal using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA). Observational studies noted this risk declines once therapy is discontinued. The WHI study did not observe an increased risk of invasive breast cancer in patients with a hysterectomy using CE alone. The risk of breast cancer in patients who are postmenopausal on hormone therapy may depend upon type of estrogen and/or progestogen, dose, timing of therapy initiation, duration of therapy, route of administration, and individual patient characteristics (AACE/ACE [Cobin 2017]; NAMS 2022). Hormone therapy may be associated with increased breast density (NAMS 2022); an increase in abnormal mammogram findings requiring further evaluation has been reported with estrogen alone or in combination with progestogen therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: Do not use estrogens with or without progestogen to prevent dementia. In the Women's Health Initiative Memory Study (WHIMS), an increased incidence of probable dementia was observed in patients ≥65 years of age taking CE alone or in combination with MPA. It is unknown if these findings apply to younger patients who are postmenopausal. However, hormone therapy is not recommended at any age to prevent or treat cognitive decline or dementia (AACE [Goodman 2011]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometrial cancer: The use of unopposed estrogen in patients with a uterus is associated with an increased risk of endometrial cancer. The addition of a progestogen to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Perform adequate diagnostic measures, including endometrial sampling if indicated, to rule out malignancy in patients who are postmenopausal with undiagnosed abnormal vaginal bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. The risk of endometrial cancer appears to be dose and duration dependent, greatest with use ≥5 years, and may persist following discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometriosis: Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestogen in patients with residual endometriosis posthysterectomy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased in patients with preexisting hypertriglyceridemia; discontinue if pancreatitis occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cancer: Available information related to the use of menopausal estrogen or estrogen/progestogen therapy and risk of ovarian cancer is inconsistent. If an association is present, the absolute risk is likely rare and may be influenced by duration of therapy (AACE [Goodman 2011]; ES [Stuenkel 2015]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue pending examination if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use caution in patients with asthma; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Do not use estrogens with or without progestogen to prevent cardiovascular disease. The WHI studies reported increased risk of deep vein thrombosis (DVT) and stroke with CE, and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) with CE with MPA in patients who are postmenopausal 50 to 79 years of age. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Manage risk factors appropriately; discontinue use immediately if adverse cardiovascular events occur or are suspected. Due to possible lower risk of thrombotic events, transdermal administration may be preferred for treating vasomotor symptoms of menopause in patients with risk factors for cardiovascular disease (AACE/ACE [Cobin 2017]; ACOG 556 2013; ES [Stuenkel 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: May impair glucose tolerance; use caution in patients with diabetes. Prior to therapy, consider age, cardiovascular and metabolic risk factors in patients previously diagnosed with diabetes (AACE/ACE [Cobin 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Use with caution in patients with diseases that may be exacerbated by fluid retention, including cardiac or renal dysfunction; consider discontinuation of therapy if medically concerning fluid retention occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epilepsy: Use caution in patients with epilepsy; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in patients with hereditary angioedema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoparathyroidism: Use caution in patients with hypoparathyroidism; estrogen-induced hypocalcemia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use caution in patients with migraine; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Otosclerosis: Use caution in patients with otosclerosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with porphyria; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematosus: Use with caution in patients with systemic lupus erythematosus; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Whenever possible, discontinue estrogens at least 4 to 6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Tablets may contain lactose; use caution in patients with galactose intolerance, lactase deficiency, or glucose-galactose metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of use: Not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Genitourinary syndrome of menopause: Low-dose vaginal estrogen is preferred over systemic therapy for genitourinary syndrome of menopause (GSM) in the absence of vasomotor symptoms due to increased efficacy and decreased systemic effects (eg, cardiovascular effects, cancer risk) (Crandall 2018; NAMS 2020; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis use: In patients with premature menopause, hormone therapy to prevent bone loss may be used unless otherwise contraindicated; reassess therapy when the average age of menopause is reached. It is also an appropriate bone-active therapy for patients with vasomotor symptoms who are &lt;60 years of age or within 10 years of menopause onset. Consider use in patients at high risk of fractures who are not candidates for other osteoporosis therapies (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Risks vs benefits: When used for the relief of menopausal symptoms or increased risk of bone fracture/loss, the benefit-risk of hormone therapy is most favorable if started in patients who have no contraindications to therapy, are &lt;60 years of age, within 10 years of menopause onset, have a favorable lipid profile, and do not have the factor V Leiden genotype or metabolic syndrome. Consider cardiovascular disease risk factors when evaluating therapy and route of administration (AACE/ACE [Cobin 2017]; NAMS 2022). Use for the shortest duration possible at the lowest effective dose consistent with treatment goals and risks for the individual patient. Reevaluate patients as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from WHI studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in women who were postmenopausal. Assume outcomes reported from clinical trials using CE with or without MPA to be similar for other doses and other dosage forms of estrogens and progestogens until comparable data become available.</p></div>
<div class="block foc drugH1Div" id="F167170"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Twice Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CombiPatch: estradiol 0.05 mg and norethindrone acetate 0.14 mg per day (8 ea); 0.05/0.25: Estradiol 0.05 mg and norethindrone acetate 0.25 mg per day (8 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Activella: estradiol 1 mg and norethindrone acetate 0.5 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amabelz: estradiol 1 mg and norethindrone acetate 0.5 mg [DSC], estradiol 0.5 mg and norethindrone acetate 0.1 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lopreeza: estradiol 1 mg and norethindrone acetate 0.5 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mimvey: estradiol 1 mg and norethindrone acetate 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1/0.5: Estradiol 1 mg and norethindrone acetate 0.5 mg, estradiol 0.5 mg and norethindrone acetate 0.1 mg, estradiol 1 mg and norethindrone acetate 0.5 mg</p></div>
<div class="block geq drugH1Div" id="F167158"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F167177"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, twice-weekly</b> (CombiPatch Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05-0.14 mg/day (per each): $37.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05-0.25 mg/day (per each): $37.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Activella Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1-0.5 mg (per each): $12.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Amabelz Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5-0.1 mg (per each): $4.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Estradiol-Norethindrone Acet Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5-0.1 mg (per each): $4.44 - $6.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1-0.5 mg (per each): $4.89 - $5.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Mimvey Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1-0.5 mg (per each): $4.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52912008"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Twice Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Estalis: estradiol 0.05 mg and norethindrone acetate 0.14 mg per day (8 ea); estradiol 0.05 mg and norethindrone acetate 0.25 mg per day (8 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Activelle: estradiol 1 mg and norethindrone acetate 0.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Activelle LD: estradiol 0.5 mg and norethindrone acetate 0.1 mg</p></div>
<div class="block adm drugH1Div" id="F167172"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Take at the same time each day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transdermal patch:</b> Apply to smooth (fold free), clean, dry skin. Do not apply transdermal patch to breasts; apply to lower abdomen, avoiding waistline (Estalis [Canadian product] may be applied to lower abdomen or buttocks). Do not apply to oily, damaged or irritated skin. Rotate application sites; allow at least a 1-week interval before applying to the same site. Hold system firmly in place for ≥10 seconds. If system falls off, the same system may be applied to another area of the lower abdomen or a new system may be applied if necessary (continue with original treatment schedule). Wear only 1 system during the dosing interval. Do not expose the applied transdermal system to the sun for long periods of time. Following removal of the system, allow area to dry for 15 minutes, then gently rub with an oil-based cream or lotion if needed to remove any remaining adhesive. Apply the patch at any time in patients not previously using oral estrogen or estrogen/progestogen therapy. Complete the current cycle before applying the patch in patients receiving oral therapy. If bleeding occurs when the oral cycle is completed, the first day of bleeding is an appropriate time to start the patch.</p></div>
<div class="block hazard drugH1Div" id="F49132512"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F167171"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis prevention (tablet):</b> Prevention of postmenopausal osteoporosis</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: For use only in patients at significant risk of postmenopausal osteoporosis; consider use of nonestrogen medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary amenorrhea, hypoestrogenism (patch):</b> Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure in patients with a uterus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause</b>
<b>(patch, tablet):</b> Treatment of moderate to severe vasomotor symptoms associated with menopause.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vulvar and vaginal atrophy associated with menopause</b>
<b>(patch, tablet):</b> Treatment of moderate to severe vulvar and vaginal atrophy associated with menopause.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: When used solely for the treatment of vulvar and vaginal atrophy, consider topical vaginal products.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The International Society for the Study of Women’s Sexual Health and The North American Menopause Society have endorsed the term genitourinary syndrome of menopause (GSM) as new terminology for vulvovaginal atrophy. The term GSM encompasses all genital and urinary signs and symptoms associated with a loss of estrogen due to menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25160739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25160739'])">Ref</a></span>).</p></div>
<div class="block mst drugH1Div" id="F50169570"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Estrogens (oral or topical patch products only), with or without progestins, are identified in the Beers Criteria as potentially inappropriate medications to be avoided in postmenopausal patients ≥65 years of age (independent of diagnosis or condition) due to their carcinogenic potential (breast and endometrium) and lack of cardioprotection or cognitive protection. Starting therapy in postmenopausal patients ≥60 years of age has greater risks (eg, heart disease, stroke, blood clots, dementia) than benefits. In postmenopausal patients already taking systemic estrogens, consider deprescribing (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F167197"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F167165"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Estrogen Derivatives may enhance the adverse/toxic effect of Chlorprothixene. Estrogen Derivatives may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Estrogen Derivatives may diminish the diagnostic effect of Cosyntropin.  Management: Discontinue estrogen containing drugs 4 to 6 weeks prior to cosyntropin (ACTH) testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Estrogen Derivatives may diminish the therapeutic effect of Growth Hormone Analogs.  Management: Initiate somapacitan at 2 mg once weekly in patients receiving oral estrogens. Monitor for reduced efficacy of growth hormone analogs; increased doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): Estrogen Derivatives may increase the serum concentration of Hydrocortisone (Systemic). Estrogen Derivatives may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Estrogen Derivatives may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Estrogen Derivatives may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking estrogen derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Estrogen Derivatives. Protease Inhibitors may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Estrogen Derivatives may enhance the adverse/toxic effect of Raloxifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Estrogen Derivatives may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Estrogen Derivatives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F167184"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Folic acid absorption may be decreased.</p></div>
<div class="block pri drugH1Div" id="F167178"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Do not use estradiol/norethindrone during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block brc drugH1Div" id="F4145989"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Estrogens and progestogens are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F22453354"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis.</p></div>
<div class="block mop drugH1Div" id="F167168"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to therapy, baseline risk for breast cancer and CVD. During therapy, age appropriate breast and pelvic exams; BP; unscheduled bleeding lasting &gt;6 months for endometrial pathology (sooner in patients with obesity, diabetes, or a history of endometrial cancer); serum triglycerides (2 weeks after starting therapy in patients with baseline level &gt;200 mg/dL); TSH (6 to 12 weeks after starting oral therapy in patients taking thyroid replacement) (ES [Stuenkel 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">Menopausal symptoms: Efficacy beginning 1 to 3 months after starting therapy, then every 6 to 12 months as appropriate. Evaluate duration of treatment at least annually (ES [Stuenkel 2015]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Monitoring of FSH and serum estradiol is not useful when managing vasomotor symptoms or genitourinary symptoms of menopause.</p>
<p style="text-indent:-2em;margin-left:4em;">Prevention of osteoporosis: Bone density measurement</p></div>
<div class="block phk drugH1Div" id="F167174"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;text-align:justify;display:inline">See individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Patch: Average serum estradiol concentrations (C<sub>avg</sub>): 45 to 50 pg/mL</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Tablet: Estradiol 5 to 8 hours; Norethindrone: 0.5 to 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Tablet: Estradiol 12 to 14 hours; Norethindrone: 8 to 11 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F167179"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Estalis | Estracomb | Estragest tts | Evorel conti | Evorel sequi | Trial | Trial combi l.a. | Trial gest | Trisequens</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estalis | Estracomb | Kliogest | Mericomb | Merigest | Perikliman | Trisequens</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Estalis | Estalis continuous | Estracombi | Kliogest | Kliovance | Trisequens</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estalis | Estracombi | Kliogest | Novofem | Trisequens</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliogest | Novofem | Pausogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Cliane | Estalis | Estracomb | Estragest tts | Gineane | Ginedisc 50 plus | Mericomb | Merigest | Natifa pro | Natifa pro ubd | Suprema | Systen conti | Systen Sequi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estalis | Estracomb | Estragest tts | Estranor Sandoz | Kliogest n | Mericomb | Systen conti | Trisequens n</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Cliane | Estracomb | Estragest tts | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Compound estradiol | Compound estradiol valerate | Kliogest | Tie tie shu | Trisequens</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cliane | Estracomb | Estragest tts | Evorel conti | Evorel sequi | Trisequens</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estalis | Estracomb | Gynovel | Kliane | Kliogest | Noresmea | Novofem | Pausogest | Systen conti | Systen Sequi | Triaklim | Trisequens</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Clionara | Cliovelle | Estalis | Estracomb | Estramon comp | Estramon conti | Gynamon | Kliogest | Mericomb | Merigest | Novofem | Sequidot | Trisequens</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Clibon | Estracomb | Evorel conti | Trisequens</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cliane | Estracomb | Estragest tts | Trisequens</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliane | Kliogest | Novofem | Trisequens</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Absorlent plus | Activelle | Duofemme | Estalis | Estracomb | Eviana | Merigest | Merigest combi | Trisequens</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Cliovelle | Estalis | Estracomb | Evorel conti | Evorel sequi | Kliogest | Mericomb | Merigest | Novofem | Trisekvens</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Kliogest | Novofemme | Trisequens</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Adgyn combi | Climagest | Climesse | Elleste duet | Elleste duet conti | Evorel conti | Evorel sequi | Femtab | Kliofem | Kliovance | Novofem | Nuvelle | Trisequens | Trisequens organon</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Estalis | Estalis Sequidot | Estracomb | Evorel sequi | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliogest | Novofem | Trisequens</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Estragest tts | Kliogest | Novofem | Pausogest | Triaklim | Trisequens n | Tulita</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cliane | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Elleste duet | Estalis | Estracombi | Evorel conti | Evorel sequi | Kliogest | Novofem | Trisequens</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Evorel conti | Evorel sequi | Kliogest | Novofem | Trisequens</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Combestril | Estalis | Estracomb | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Menoaid</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Cliane | Cliovelle | Combitran | Esdiol half | Esdiol-half | Estracomb | Eveclin | Eveclin Half | Eveprem | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Estracomb | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliogest | Novofem | Pausogest | Triaklim | Trisequens</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estalis | Estracomb | Estracombi | Kliogest | Mericomb | Merigest | Novofem | Trisequens</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Evorel conti | Kliane | Kliogest | Novofem | Pausogest | Triaklim | Trisequens</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cliane | Estalis | Estracomb | Evorel conti</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Cliovelle | Estalis | Estracomb | Eviana | Kliogest | Noresmea | Novofem | Trisekvens | Trisekvens forte</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cliane | Estalis continuous | Kliogest | Kliovance | Trisequens</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cliane | Estracomb | Estragest tts | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Estracomb | Klian | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Cliovelle | Estalis | Estracomb | Kliogest | Novofem | Systen conti | Systen Sequi | Trisequens</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Activella | Amabelz | Combipatch | Estradiol / norethindrone acetate | Estradiol and norethindrone | Lopreeza | Mimvey</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estalis | Estracomb | Kliogest | Novofem | Trisequens</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cliane</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Kliogest</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Eviana | Kliogest | Pausogest | Revmelid | Triaklim | Trisequens</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Cliovellan | Cliovelle | Estalis | Femanor | Femasekvens | Noresmea | Sequidot</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Kliogest | Novofem | Trisequens</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracomb | Gynovel | Kliogest | Novofem | Pausogest | Systen conti | Systen Sequi | Trisequens</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Kliogest</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracombi | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Covina | Gindolin | Havina | Heana | Jinberchanq | Kliogest | Komeni | Megast | Norestrin | Sevina | Trisequens</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Kliogest | Pausogest | Triaklim | Trisequens</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Cliane | Estracomb | Estragest tts | Evorel conti | Evorel sequi | Trisequens</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cliane | Estracomb | Estragest tts | Kliogest | Trisequens</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Activelle | Estracombi | Estro-pause n | Evorel conti | Evorel sequi | Kliogest | Novofem</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30301734">
<a name="30301734"></a>Ackerman KE, Singhal V, Baskaran C, et al. Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial. <i>Br J Sports Med.</i> 2019;53(4):229-236. doi:10.1136/bjsports-2018-099723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/30301734/pubmed" id="30301734" target="_blank">30301734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31603998">
<a name="31603998"></a>Ackerman KE, Singhal V, Slattery M, et al. Effects of estrogen replacement on bone geometry and microarchitecture in adolescent and young adult oligoamenorrheic athletes: a randomized trial. <i>J Bone Miner Res.</i> 2020;35(2):248-260. doi:10.1002/jbmr.3887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/31603998/pubmed" id="31603998" target="_blank">31603998</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Activella (estradiol and norethindrone) [prescribing information]. Bridgewater, NJ: Amneal Specialty; April 2020.</div>
</li>
<li>
<div class="reference">
                  Activelle (estradiol and norethindrone) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada; June 2016.</div>
</li>
<li>
<div class="reference">
                  Activelle LD (estradiol and norethindrone) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada; June 2016.</div>
</li>
<li>
<div class="reference">
                  Amabelz (estradiol and norethindrone) [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635705">
<a name="23635705"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol. 2013;121(4):887-890. doi:10.1097/01.AOG.0000428645.90795.d9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/23635705/pubmed" id="23635705" target="_blank">23635705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812486">
<a name="23812486"></a>American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 565: Hormone therapy and heart disease. Obstet Gynecol. 2013 Jun;121(6):1407-10. doi:10.1097/01.AOG.0000431053.33593.2d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/23812486/pubmed" id="23812486" target="_blank">23812486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28426619">
<a name="28426619"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 698: Hormone therapy in primary ovarian insufficiency. <i>Obstet Gynecol.</i> 2017;129(5):e134-e141. doi:10.1097/AOG.0000000000002044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/28426619/pubmed" id="28426619" target="_blank">28426619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15082697">
<a name="15082697"></a>Anderson GL, Limacher M, Assaf AR, et al. Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial. <i>JAMA</i>. 2004;291(14):1701-1712.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/15082697/pubmed" id="15082697" target="_blank">15082697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause-2017 update. <i>Endocr Pract</i>. 2017;23(7):869-880. doi:10.4158/EP171828.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  CombiPatch (estradiol and norethindrone) [prescribing information]. Miami, FL: Noven Therapeutics; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28816933">
<a name="28816933"></a>Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i>. 2018;25(1):11-20. doi:10.1097/GME.0000000000000956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/28816933/pubmed" id="28816933" target="_blank">28816933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Estalis.1">
<a name="Estalis.1"></a>Estalis (estradiol/norethindrone) transdermal therapeutic system [product monograph] Boucherville, Quebec, Canada: Sandoz Canada Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193047">
<a name="22193047"></a>Goodman NF, Cobin RH, Ginzburg SB, et al; American Association of Clinical Endocrinologists (AACE). American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. <i>Endocr Pract</i>. 2011;17(suppl 6):1-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/22193047/pubmed" id="22193047" target="_blank">22193047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28368518">
<a name="28368518"></a>Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2017;102(5):1413-1439. doi: 10.1210/jc.2017-00131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/28368518/pubmed" id="28368518" target="_blank">28368518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16476878">
<a name="16476878"></a>Hsia J, Langer RD, Manson JE, et al. Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative. <i>Arch Intern Med</i>. 2006;166(3):357-365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/16476878/pubmed" id="16476878" target="_blank">16476878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10818427">
<a name="10818427"></a>Kalantaridou SN, Nelson LM. Premature ovarian failure is not premature menopause. <i>Ann N Y Acad Sci.</i> 2000;900:393-402. doi:10.1111/j.1749-6632.2000.tb06251.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/10818427/pubmed" id="10818427" target="_blank">10818427</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lopreeza (estradiol/norethindrone) [prescribing information]. Glasglow, KY; Amneal Pharmaceuticals, August 2014.</div>
</li>
<li>
<div class="reference">
                  Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022.</div>
</li>
<li>
<div class="reference">
                  Mimvey (estradiol/norethindrone) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; January 2022.</div>
</li>
<li>
<div class="reference">
                  Mimvey Lo (estradiol/norethindrone) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19196677">
<a name="19196677"></a>Nelson LM. Clinical practice. Primary ovarian insufficiency.<i> N Engl J Med</i>. 2009;360(6):606-614. doi:10.1056/NEJMcp0808697<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/19196677/pubmed" id="19196677" target="_blank">19196677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32852449">
<a name="32852449"></a>North American Menopause Society (NAMS). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. <i>Menopause</i>. 2020;27(9):976-992. doi:10.1097/GME.0000000000001609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/32852449/pubmed" id="32852449" target="_blank">32852449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35797481">
<a name="35797481"></a>North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/35797481/pubmed" id="35797481" target="_blank">35797481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24905063">
<a name="24905063"></a>Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. <i>J Clin Endocrinol Metab</i>. 2014;99(9):3418-3426. doi:10.1210/jc.2013-4145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/24905063/pubmed" id="24905063" target="_blank">24905063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25160739">
<a name="25160739"></a>Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. <i>Menopause</i>. 2014;21(10):1063-8. doi:10.1097/GME.0000000000000329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/25160739/pubmed" id="25160739" target="_blank">25160739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20230416">
<a name="20230416"></a>Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. <i>J Thromb Haemost.</i> 2010;8(5):979-986. doi:10.1111/j.1538-7836.2010.03839.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/20230416/pubmed" id="20230416" target="_blank">20230416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117397">
<a name="12117397"></a>Rossouw JE, Anderson GL, Prentice RL, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial. <i>JAMA</i>. 2002;288(3):321-333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/12117397/pubmed" id="12117397" target="_blank">12117397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771112">
<a name="12771112"></a>Shumaker SA, Legault C, Rapp SR, et al. Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial. <i>JAMA</i>. 2003;289(20):2651-2662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/12771112/pubmed" id="12771112" target="_blank">12771112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline [published online ahead of print October 7, 2015]. <i>J Clin Endocrinol Metab</i>. 2015:jc20152236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/estradiol-and-norethindrone-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration, Department of Health and Human Services. WHIMS Study on Estrogen/Progestin. May 27, 2003. <a href="http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm</a>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8924 Version 376.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
